Abstract:Background Activin-A, a transforming growth factor β family member, is secreted by many cancer types and is often associated with poor disease prognosis. Previous studies have shown that Activin-A expression can promote cancer progression and reduce the intratumoral frequency of cytotoxic T cells. However, the underlying mechanisms and the significance of Activin-A expression for cancer therapies are unclear. Methods We analyzed the expression of the Activin-A encoding gene INHBA in melanoma patients and the influence of its gain- or loss-of-function on the immune infiltration and growth of BRAF -driven YUMM3.3 and iBIP2 mouse melanoma grafts and in B16 models. Using antibody depletion strategies, we investigated the dependence of Activin-A tumor-promoting effect on different immune cells. Immune-regulatory effects of Activin-A were further characterized in vitro and by an adoptive transfer of T cells. Finally, we assessed INHBA expression in melanoma patients who received immune checkpoint therapy and tested whether it impairs the response in preclinical models. Results We show that Activin-A secretion by melanoma cells inhibits adaptive antitumor immunity irrespective of BRAF status by inhibiting CD8 + T cell infiltration indirectly and even independently of CD4 T cells, at least in part by attenuating the production of CXCL9/10 by myeloid cells. In addition, we show that Activin-A/ INHBA expression correlates with anti-PD1 therapy resistance in melanoma patients and impairs the response to dual anti-cytotoxic T-Lymphocyte associated protein 4/anti-PD1 treatment in preclinical models. Conclusions Our findings suggest that strategies interfering with Activin-A induced immune-regulation offer new therapeutic opportunities to overcome CD8 T cell exclusion and immunotherapy resistance.

Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Activin A Promotes Regulatory T-cell-Mediated Immunosuppression in Irradiated Breast Cancer

Therapeutic blockade of Activin-A improves NK cell function and anti-tumor immunity

Inhibition of anti-tumor immunity by melanoma cell-derived Activin-A depends on STING

Depletion of CD4+CD25high Regulatory T Cells from Tumor Infiltrating Lymphocytes Predominantly Induces Th1 Type Immune Response in Vivo Which Inhibits Tumor Growth in Adoptive Immunotherapy

Activin receptors in human cancer: Functions, mechanisms, and potential clinical applications

Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy

Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma

TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy

CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells

Activin A, a Novel Chemokine, Induces Mouse NK Cell Migration via AKT and Calcium Signaling

Antibody-based Cancer Immunotherapy by Targeting Regulatory T Cells

Enhancing Adoptive Cell Therapy of Cancer Through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors

Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells

Improving the <i>ex vivo</i> expansion of human tumor-reactive CD8+T cells by targeting toll-like receptors

Uncovering Tumor-Promoting Roles of Activin A in Pancreatic Ductal Adenocarcinoma

Controllable Regulation of CD3ζ and MyD88 Signaling in T Cells Expands and Enhances the Neoantigen-Reactive Repertoire Resulting in Effective Antitumor Activity

Conversion of CCL18-recruited Naïve CD4+ T Cells to Tumor-Infiltrating Regulatory T Cells in Breast Cancer and Suppression of Antitumor Immunity.

Intratumoral regulatory T cells: markers, subsets and their impact on anti‐tumor immunity

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies